- Home
- JXJT vs PSTV Comparison
JXJT vs PSTV Comparison
Compare JXJT & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JXJT
- PSTV
- Stock Information
- Founded
- JXJT 2012
- PSTV 1996
- Country
- JXJT China
- PSTV United States
- Employees
- JXJT N/A
- PSTV N/A
- Industry
- JXJT Apparel
- PSTV Medical/Dental Instruments
- Sector
- JXJT Consumer Staples
- PSTV Health Care
- Exchange
- JXJT Nasdaq
- PSTV Nasdaq
- Market Cap
- JXJT 11.5M
- PSTV 9.4M
- IPO Year
- JXJT 2012
- PSTV N/A
- Fundamental
- Price
- JXJT $1.57
- PSTV $1.41
- Analyst Decision
- JXJT
- PSTV Strong Buy
- Analyst Count
- JXJT 0
- PSTV 2
- Target Price
- JXJT N/A
- PSTV $14.00
- AVG Volume (30 Days)
- JXJT 36.7K
- PSTV 84.6K
- Earning Date
- JXJT 11-01-2024
- PSTV 10-29-2024
- Dividend Yield
- JXJT N/A
- PSTV N/A
- EPS Growth
- JXJT N/A
- PSTV N/A
- EPS
- JXJT 0.48
- PSTV N/A
- Revenue
- JXJT $31,840,588.00
- PSTV $5,509,000.00
- Revenue This Year
- JXJT N/A
- PSTV $11.13
- Revenue Next Year
- JXJT N/A
- PSTV N/A
- P/E Ratio
- JXJT $3.40
- PSTV N/A
- Revenue Growth
- JXJT N/A
- PSTV 113.20
- 52 Week Low
- JXJT $1.04
- PSTV $0.97
- 52 Week High
- JXJT $8.51
- PSTV $2.78
- Technical
- Relative Strength Index (RSI)
- JXJT 38.73
- PSTV 46.79
- Support Level
- JXJT $1.40
- PSTV $1.20
- Resistance Level
- JXJT $1.75
- PSTV $1.45
- Average True Range (ATR)
- JXJT 0.14
- PSTV 0.10
- MACD
- JXJT -0.04
- PSTV 0.01
- Stochastic Oscillator
- JXJT 32.08
- PSTV 57.37
About JXJT JX Luxventure Limited
JX Luxventure Ltd is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Airline tickets and tourism services, Software Solutions for Tourism Cross-border operation, and Tourism Cross-border Merchandise. The majority of the group revenue is generated from Tourism products.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).